Business Details
Innovative Cancer Therapeutics Solutions in Cleveland
Red 5 Pharmaceuticals is an emerging start-up company dedicated to developing innovative therapeutic agents against cancer. Our focus lies in leveraging patented technology across three key biomedical areas: Chemosensitizers, Theranostic Agents, and Diagnostic Detection of Pro-Mutagenic Replication. With a team of experienced professionals, we specialize in synthesizing non-natural nucleosides and conducting rigorous pre-clinical testing to enhance chemotherapy efficacy. Our mission is to pioneer personalized medicine by creating theranostic agents that combine therapeutic and diagnostic properties, addressing critical limitations in current cancer treatments.Collaborating with leading institutions like Cleveland State University and the Cleveland Clinic Foundation, we aim to revolutionize cancer care through cutting-edge research and strategic partnerships. Our expertise spans medicinal chemistry, mechanistic enzymology, cell-based studies, and pre-clinical validation, ensuring a robust pipeline of potential breakthrough therapies.
Services
Chemosensitizers
Theranostic Agents
Diagnostic Detection
Medicinal Chemistry
Pre-Clinical Testing
Highlights and features
- We have 16 years of product development expertise in biotechnology startups.
- Our patented chemosensitizer technology enhances chemotherapy efficacy.
- Collaborations with Cleveland Clinic Foundation and Case Comprehensive Cancer Center.
- Extensive experience in nucleoside analog synthesis and pre-clinical validation.
- Led by co-founders with academic and clinical research leadership backgrounds.
Services
Chemosensitizers
Chemosensitizers are non-natural nucleosides designed to enhance chemotherapy effectiveness. By improving the potency of agents like temozolomide and cisplatin, these compounds increase treatment efficacy while reducing required dosages. This approach minimizes side effects and addresses drug resistance, offering improved outcomes for cancer patients through targeted biochemical interactions.
Theranostic Agents
Theranostic agents combine therapeutic and diagnostic functions for personalized cancer treatment. These nucleoside analogs enable real-time monitoring of drug activity within patients, allowing dosage adjustments based on individual responses. This approach improves treatment precision, reduces trial-and-error prescribing, and enhances patient safety by directly linking therapeutic delivery with diagnostic feedback mechanisms.
Diagnostic Detection
Our diagnostic detection technology identifies patients' responses to DNA-damaging therapies. By assessing pro-mutagenic replication risks, we help oncologists determine optimal treatment strategies. This capability addresses a critical clinical need by reducing uncertainty in chemotherapy selection and improving patient stratification for personalized treatment plans.
Medicinal Chemistry
The Medicinal Chemistry group synthesizes diverse nucleoside analogs with therapeutic potential. Operating advanced analytical equipment, we maintain a library of over 50 active compounds. Our researchers evaluate structure-activity relationships to optimize lead candidates, focusing on biochemical properties that enhance anti-cancer efficacy and pharmacokinetic profiles.
Pre-Clinical Testing
Pre-clinical testing evaluates compound safety and efficacy using animal models. We partner with top research institutions to conduct comprehensive validation studies. This stage provides critical proof-of-concept data, demonstrating therapeutic potential while identifying potential toxicity issues before advancing to human clinical trials.
People
Timothy Miller
Chairman and Co-Founder
Dr. Miller holds a Ph.D. in Pharmacology with 16 years of biotech startup experience. He has led cross-functional teams in clinical trial design, managed intellectual property, and published research in international journals.
Anthony Berdis
Chief Scientific Officer, Co-Founder
Dr. Berdis specializes in nucleoside analogs with 20+ years of academic research experience. He has published over 70 papers and secured funding from NIH, NSF, and the American Cancer Society for his work on DNA polymerase-targeted therapies.
Michael Gilkey
Vice President, Business Development
Mr. Gilkey brings extensive experience in commercial development and strategic partnerships. He has successfully launched multiple biotech startups and managed technology commercialization through university technology transfer offices.
Steve Goden
Director of Finance
Mr. Goden has over 30 years of financial management experience across various industries. His career includes roles at Progressive Insurance, Premier Travel Partners, and Cohesant Inc., where he managed complex financial operations and strategic planning.
Questions
What makes Red5's cancer therapies unique?
Our patented technology creates theranostic agents combining therapeutic and diagnostic functions, enabling personalized treatment monitoring and improved chemotherapy efficacy through nucleoside analogs.
How does Red5's chemosensitizer technology work?
Our non-natural nucleosides enhance standard chemotherapy agents' effectiveness by increasing their potency against cancer cells while potentially reducing required dosages and associated side effects.
What research areas does Red5 focus on?
We concentrate on three biomedical areas: chemosensitizers, theranostic agents, and diagnostic detection of pro-mutagenic replication for comprehensive cancer treatment solutions.
Who collaborates with Red5 on research projects?
We partner with Cleveland State University, the CASE Comprehensive Cancer Center, and the Cleveland Clinic Foundation for pre-clinical testing and translational research initiatives.
What experience does Red5's leadership team have?
Our founders have combined expertise in pharmacology, biochemistry, and biotechnology startups, with proven track records in clinical research, intellectual property management, and successful drug development.
